A recently published study showed the safety and efficacy of LSD-assisted psychotherapy in patients with anxiety associated with life-threatening diseases. Participants of this study were included in a prospective follow-up.
Method:
12 months after finishing LSD psychotherapy, 10 participants were tested for anxiety (STAI) and participated in a semi-structured interview. A Qualitative Content Analysis (QCA) was carried out on the interviews to elaborate about LSD effects and lasting psychological changes.
Results:
None of the participants reported lasting adverse reactions. The significant benefits as measured with the STAI were sustained over a 12-month period. In the QCA participants consistently reported insightful, cathartic and interpersonal experiences, accompanied by a reduction in anxiety (77.8%) and a rise in quality of life (66.7%). Evaluations of subjective experiences suggest facilitated access to emotions, confrontation of previously unknown anxieties, worries, resources and intense emotional peak experiences à la Maslow as major psychological working mechanisms. The experiences created led to a restructuring of the person’s emotional trust, situational understanding, habits and world view.
Conclusions:
LSD administered in a medically supervised psychotherapeutic setting can be safe and generate lasting benefits in patients with a life-threatening disease. Explanatory models for the therapeutic effects of LSD warrant further study.
AbramsonH (ed) (1967) The Use of LSD in Psychotherapy and Alcoholism. New York: Bobbs-Merrill.
2.
AdlamJZamanR (2013) The role of BDNF and memory in major depressive disorder. Psychiatr Danub2013(Suppl 2): S368–S369.
3.
BehrendtRP (2003) Hallucinations: Synchronisation of thalamocortical gamma oscillations underconstrained by sensory input. Conscious Cogn12: 413–451.
4.
BéïqueJCImadMMladenovicL. (2007) Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex. Proc Natl Acad Sci U S A104: 9870–9875.
5.
BullmoreEBarnesABassettDS. (2009) Generic aspects of complexity in brain imaging data and other biological systems. Neuroimage47: 1125–1134.
6.
Carhart-HarrisRLFristonKJ (2010) The default-mode, ego-functions and free-energy: A neurobiological account of Freudian ideas. Brain133: 1265–1283.
7.
Carhart-HarrisRLErritzoeDWilliamsT. (2012a) Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A109: 2138–2143.
8.
Carhart-HarrisRLLeechRHellyerPJ. (2014) The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. Front Hum Neurosci8: 20.
9.
Carhart-HarrisRLLeechRWilliamsTM. (2012b) Implications for psychedelic-assisted psychotherapy: Functional magnetic resonance imaging study with psilocybin. Br J Psychiatry200: 238–244.
10.
CohenJ (1960) Lysergic acid diethylamide: Side effects and complications. J Nerv Ment Dis130: 30–40.
11.
CyrM1LandryMDi PaoloT (2000) Modulation by estrogen-receptor directed drugs of 5-hydroxytryptamine-2A receptors in rat brain. Neuropsychopharmacology23: 69–78.
12.
DieschM (2014, in print) LSD: Rückkehr in die klinische Forschung. Solothurn: Nachtschatten.
13.
EliadeM (1975) Schamanismus und archaische Ekstasetechnik. Frankfurt: Suhrkamp.
14.
FiorellaDRabinRAWinterJC (1995) The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs. I: Antagonist correlation analysis. Psychopharmacology (Berl)121: 347–356.
15.
GasserP (1996) Die Psycholytische Therapie in der Schweiz von 1988 – 1993. Schweiz Arch Neurol Psych147: 59–65.
16.
GasserPHolsteinDMichelY. (2014) Safety and efficacy of LSD-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis202: 513–520.
17.
Gouzoulis-MayfrankESchreckenbergerMSabriO. (1999) Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG. Neuropsychopharmacology20: 565–581.
GriffithsRRRichardsWAMcCannU. (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology187: 268–283.
20.
GrobCSDanforthALChopraGS. (2011) Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiat68: 71–78.
21.
GrofS (1975) Realms of the Human Unconscious. New York, NY: Viking.
GrofSGoodmanLERichardsWA. (1973) LSD-assisted psychotherapy in patients with terminal cancer. Int Pharmacopsychiatry8: 129–144.
24.
GusnardDAAkbudakEShulman. (2007) Medial prefrontal cortex and self-referential mental activity: relation to a default mode of brain function. Proc Natl Acad Sci U S A98: 4259–64.
25.
HagmannPCammounLGigandetX. (2008) Mapping the structural core of human cerebral cortex. PLoS Biol6: e159.
26.
HalberstadtALGeyerMA (2011) Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology61: 364–381.
27.
HaririARDrabantEMWeinbergerDR (2006) Imaging genetics: Perspectives from studies of genetically driven variation in serotonin function and corticolimbic affective processing. Biol Psychiatry59: 888–897.
28.
HintzenAPassieT (2010) The pharmacology of LSD. Oxford, UK: Oxford University Press.
29.
JamesW (1902) The varieties of religious experience. New York: Longmans Green.
30.
JiangC1SaltonSR (2013) The role of neurotrophins in major depressive disorder. Transl Neurosci4: 46–58.
31.
KastE (1967) Attenuation and anticipation: A therapeutic use of lysergic acid diethylamide. Psychiatric Quarterly41: 646–657.
32.
KirchnerK (2010) LSD-supported psychotherapy: effects on daily life and longterm changes. MA Thesis, University of Zurich, Switzerland.
33.
KurlandAA (1985) LSD in the supportive care of the terminally ill cancer patient. J Psychoactive Drugs17: 279–290.
34.
LeunerH (1962) Die experimentelle Psychose. Berlin, Göttingen, Heildelberg: Springer.
35.
LeunerH (1967) Present state of psycholytic therapy and its possibilities. In: AbramsonHA (ed) The use of LSD in Psychotherapy and Alcoholism. New York et al.: Bobbs-Merrill, pp. 101–116.
36.
LeunerH (1981) Halluzinogene. Bern: Huber.
37.
McGlothlinWCohenSMcGlothlinMS (1967) Long lasting effects of LSD on normals. Arch Gen Psychiat17: 521–532.
38.
MacLeanKAJohnsonMWGriffithsRR (2011) Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol25: 1453–1461.
39.
MallesonN (1971) Acute adverse reactions to LSD in clinical and experimental use in the United Kingdom. Brit J Psychiatry118: 229–230.
40.
MAPS (2007) LSD-assisted psychotherapy in persons suffering from anxiety associated with advanced-stage life threatening diseases. Study Report. Available at: http://maps.org/pdf/LDA1_FINAL_CSR_20Aug13.pdf (accessed 10 October 2014).
41.
Martín-RuizRPuigMVCeladaP. (2001) Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through a glutamate-dependent mechanism. J Neurosci21: 9856–9866.
42.
MaslowA (1962) Lessons from the peak experience. J Humanistic Psychol2: 9–18.
43.
MaslowA (1970) Religions, values, and peak experiences. New York: Viking.
44.
MaxwellJA (2009) Designing a qualitative study. In: BickmanLRogDJ (eds) Handbook of Applied Social Research Methods. Los Angeles, CA: Sage, pp. 214–253.
45.
MayringPGlaeser-ZikudaM (eds) (2008) Die Praxis der qualitativen Inhaltsanalyse. Weinheim: Beltz.
46.
MeertTF (1996) Serotonin mechanisms in antipsychotic treatment: evidence from drug discrimination studies. In: KaneJMMollerH-JAwoutersF (eds) Serotonin in antipsychotic treatment. New York: Marcel Dekker, pp. 109–130.
NorthoffG (2007) Psychopathology and pathophysiology of the self in depression – neuropsychiatric hypothesis. J Affect Disord104: 1–14.
49.
PahnkeWN (1969) The psychedelic mystical experience in the human encounter with death. Harvard Theol Rev62: 1–21.
50.
PahnkeWNKurlandAAUngerS. (1970) The experimental use of psychedelic (LSD) psychotherapy. JAMA212: 1856–1863.
51.
PassieTHalpernJHStichtenothDO. (2008) The pharmacology of lysergic acid diethylamide: A review. CNS Neurosci Ther14: 295–314.
52.
PizzagalliDA (2011) Frontocingulate dysfunction in depression: toward biomarkers of treatment response. Neuropsychopharmacology36: 183–206.
53.
PiercePAPeroutkaSJ (1989) Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex. Psychopharmacology98: 118–122.
54.
PuigMVCeladaPDíaz-MataixL. (2003) In vivo modulation of the activity of pyramidal neurons in the rat medial prefrontal cortex by 5-HT2A receptors: relationship to thalamocortical afferents. Cereb Cortex13: 870–82.
55.
RaichleME (1998) The neural correlates of consciousness: An analysis of cognitive skill learning. Philos Trans R Soc Lond B Biol Sci353: 1889–1901.
56.
RichardsWARheadJCDileoFB. (1977) The peak experience variable in DPT-assisted psychotherapy with cancer patients. J Psychoactive Drugs9: 1–10.
57.
SavageCFadimanJMogarR. (1966) The effects of psychedelic (LSD) therapy on values, personality, and behavior. Int J Neuropsychiatry2: 241–254.
58.
SchultesREHofmannA (1980) Plants of the Gods: Origins of Hallucinogenic Use. London: Hutchinson.
59.
Schweizerische Krebsliga (2005) Schlussbericht Bestandesaufnahme psychosoziale Onkologie in der Schweiz. Bern: Krebsliga Schweiz.
60.
SewellRAHalpernJHPopeHGJr. (2006) Response of cluster headache to psilocybin and LSD. Neurology66: 1920–1922.
61.
SpielbergerCSGorsuchRLLusheneRE (1970) Manual for the State Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press.
62.
StuhrmannA1SuslowTDannlowskiU (2011) Facial emotion processing in major depression: A systematic review of neuroimaging findings. Biol Mood Anxiety Disord1: 10.
63.
TerrillJames (1962) The nature of the LSD experience. J Nerv Ment Dis135: 425–29.
64.
UngerSM (1963) Mescaline, LSD, psilocybin, and personality change. Psychiatry26: 111–125.
65.
VaidyaVAMarekGJAghajanianGK. (1997) 5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex. J Neurosci17: 2785–2795.
66.
Vázquez-BorsettiP1CortésRArtigasF (2009) Pyramidal neurons in rat prefrontal cortex projecting to ventral tegmental area and dorsal raphe nucleus express 5-HT2A receptors. Cereb Cortex19: 1678–1686.
67.
VollenweiderFXGeyerMA (2001) A systems model of altered consciousness: Integrating natural and drug-induced psychoses. Brain Res Bull56: 495–507.
68.
VollenweiderFXKometerM (2010) The neurobiology of psychedelic drugs: Implications for the treatment of mood disorders. Nat Rev Neurosci11: 642–651.
69.
VollenweiderFXLeendersKLScharfetterC. (1997) Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology16: 357–372.
70.
VollenweiderFXVontobelPHellD. (1999) 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man – a PET study with [11C]raclopride. Neuropsychopharmacology20: 424–433.
71.
VollenweiderFXVollenweider-ScherpenhuyzenMFBäblerA. (1998) Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport9: 3897–3902.
72.
WeissRS (1995) Learning from Strangers: The Art and Method of Qualitative Interview Studies. New York, NY: Free Press.
73.
WinterJCEcklerJRRabinRA (2004) Serotonergic/glutamatergic interactions: The effects of mGlu2/3 receptor ligands in rats trained with LSD and PCP as discriminative stimuli. Psychopharmacology (Berl)172: 233–240.
